1 Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk

Eileen O. Dareng¹*, Jonathan P. Tyrer²*, Daniel R. Barnes¹, Michelle R. Jones³, Xin Yang¹, 2 Katja K.H. Aben^{4, 5}, Muriel A. Adank⁶, Simona Agata⁷, Irene L. Andrulis^{8, 9}, Hoda Anton-3 Culver¹⁰, Natalia N. Antonenkova¹¹, Gerasimos Aravantinos¹², Banu K. Arun¹³, Annelie 4 Augustinsson¹⁴, Judith Balmaña^{15, 16}, Elisa V. Bandera¹⁷, Rosa B. Barkardottir^{18, 19}, Daniel 5 Barrowdale¹, Matthias W. Beckmann²⁰, Alicia Beeghly-Fadiel²¹, Javier Benitez^{22, 23}, Marina 6 Bermisheva²⁴, Marcus Q. Bernardini²⁵, Line Bjorge^{26, 27}, Amanda Black²⁸, Natalia V. 7 Bogdanova^{11, 29, 30}, Bernardo Bonanni³¹, Ake Borg³², James D. Brenton³³, Agnieszka 8 Budzilowska³⁴, Ralf Butzow³⁵, Saundra S. Buys³⁶, Hui Cai²¹, Maria A. Caligo³⁷, Ian Campbell³⁸, 9 ³⁹, Rikki Cannioto⁴⁰, Hayley Cassingham⁴¹, Jenny Chang-Claude^{42, 43}, Stephen J. Chanock⁴⁴, 10 Kexin Chen⁴⁵, Yoke-Eng Chiew^{46, 47}, Wendy K. Chung⁴⁸, Kathleen B.M. Claes⁴⁹, Sarah 11 Colanna³⁶, GEMO Study Collaborators⁵⁰⁻⁵², GC-HBOC study Collaborators⁵³, EMBRACE 12 Collaborators¹, Linda S. Cook^{54, 55}, Fergus J. Couch⁵⁶, Mary B. Daly⁵⁷, Fanny Dao⁵⁸, Eleanor 13 Davies⁵⁹, Miguel de la Hoya⁶⁰, Robin de Putter⁴⁹, Joe Dennis¹, Allison DePersia^{61, 62}, Peter 14 Devilee^{63, 64}, Orland Diez^{65, 66}, Yuan Chun Ding⁶⁷, Jennifer A. Doherty⁶⁸, Susan M. Domchek⁶⁹, 15 Thilo Dörk³⁰, Andreas du Bois^{70, 71}, Matthias Dürst⁷², Diana M. Eccles⁷³, Heather A. Eliassen⁷⁴, 16 ⁷⁵, Christoph Engel^{76, 77}, D. Gareth Evans^{78, 79}, Peter A. Fasching^{20, 80}, James M. Flanagan⁸¹, 17 Lenka Foretova⁸², Renée T. Fortner⁴², Eitan Friedman^{83, 84}, Patricia A. Ganz⁸⁵, Judy Garber⁸⁶, 18 Francesca Gensini⁸⁷, Graham G. Giles⁸⁸⁻⁹⁰, Gord Glendon⁸, Andrew K. Godwin⁹¹, Marc T. 19 Goodman⁹², Mark H. Greene⁹³, Jacek Gronwald⁹⁴, OPAL Study Group⁹⁵, AOCS Group^{38, 46}, 20 Eric Hahnen^{53, 96}, Christopher A. Haiman⁹⁷, Niclas Håkansson⁹⁸, Ute Hamann⁹⁹, Thomas V.O. 21 Hansen¹⁰⁰, Holly R. Harris^{101, 102}, Mikael Hartman^{103, 104}, Florian Heitz^{70, 71, 105}, Michelle A.T. 22 Hildebrandt¹⁰⁶, Estrid Høgdall^{107, 108}, Claus K. Høgdall¹⁰⁹, John L. Hopper⁸⁹, Ruea-Yea 23 Huang¹¹⁰, Chad Huff¹⁰⁶, Peter J. Hulick^{61, 62}, David G. Huntsman¹¹¹⁻¹¹⁴, Evgeny N. Imyanitov¹¹⁵, 24 KConFab Investigators³⁸, HEBON Investigators¹¹⁶, Claudine Isaacs¹¹⁷, Anna Jakubowska^{94, 118}, 25 Paul A. James^{39, 119}, Ramunas Janavicius^{120, 121}, Allan Jensen¹⁰⁷, Oskar Th. Johannsson¹²², Esther 26 M. John^{123, 124}, Michael E. Jones¹²⁵, Daehee Kang¹²⁶⁻¹²⁸, Beth Y. Karlan¹²⁹, Anthony 27 Karnezis¹³⁰, Linda E. Kelemen¹³¹, Elza Khusnutdinova^{24, 132}, Lambertus A. Kiemeney⁴, Byoung-28 Gie Kim¹³³, Susanne K. Kjaer^{107, 109}, Ian Komenaka¹³⁴, Jolanta Kupryjanczyk³⁴, Allison W. 29 Kurian^{123, 124}, Ava Kwong¹³⁵⁻¹³⁷, Diether Lambrechts^{138, 139}, Melissa C. Larson¹⁴⁰, Conxi 30 Lazaro¹⁴¹, Nhu D. Le¹⁴², Goska Leslie¹, Jenny Lester¹²⁹, Fabienne Lesueur^{51, 52, 143}, Douglas A. 31 Levine^{58, 144}, Lian Li⁴⁵, Jingmei Li¹⁴⁵, Jennifer T. Loud⁹³, Karen H. Lu¹⁴⁶, Jan Lubiński⁹⁴, Eva 32 Machackova⁸², Phuong L. Mai¹⁴⁷, Siranoush Manoukian¹⁴⁸, Jeffrey R. Marks¹⁴⁹, Rayna Kim 33 Matsuno¹⁵⁰, Keitaro Matsuo^{151, 152}, Taymaa May²⁵, Lesley McGuffog¹, John R. McLaughlin¹⁵³, 34

1

Iain A. McNeish^{154, 155}, Noura Mebirouk^{51, 52, 143}, Usha Menon¹⁵⁶, Austin Miller¹⁵⁷, Roger L. 35 Milne⁸⁸⁻⁹⁰, Albina Minlikeeva¹⁵⁸, Francesmary Modugno^{159, 160}, Marco Montagna⁷, Kirsten B. 36 Moysich¹⁵⁸, Elizabeth Munro^{161, 162}, , Katherine L. Nathanson⁶⁹, Susan L. Neuhausen⁶⁷, Heli 37 Nevanlinna¹⁶³, Joanne Ngeow Yuen Yie^{164, 165}, Henriette Roed Nielsen¹⁶⁶, Finn C. Nielsen¹⁰⁰, 38 Liene Nikitina-Zake¹⁶⁷, Kunle Odunsi¹⁶⁸, Kenneth Offit^{169, 170}, Edith Olah¹⁷¹, Siel Olbrecht¹⁷², 39 Olufunmilayo I. Olopade¹⁷³, Sara H. Olson¹⁷⁴, Håkan Olsson¹⁴, Ana Osorio^{23, 175}, Laura Papi⁸⁷, 40 Sue K. Park¹²⁶⁻¹²⁸, Michael T. Parsons¹⁷⁶, Harsha Pathak⁹¹, Inge Sokilde Pedersen¹⁷⁷⁻¹⁷⁹, Ana 41 Peixoto¹⁸⁰, Tanja Pejovic^{161, 162}, Pedro Perez-Segura⁶⁰, Jennifer B. Permuth¹⁸¹, Beth Peshkin¹¹⁷, 42 Paolo Peterlongo¹⁸², Anna Piskorz³³, Darva Prokofyeva¹⁸³, Paolo Radice¹⁸⁴, Johanna Rantala¹⁸⁵, 43 Marjorie J. Riggan¹⁸⁶, Harvey A. Risch¹⁸⁷, Cristina Rodriguez-Antona^{22, 23}, Eric Ross¹⁸⁸, Mary 44 Anne Rossing^{101, 102}, Ingo Runnebaum⁷², Dale P. Sandler¹⁸⁹, Marta Santamariña^{175, 190, 191}, Penny 45 Soucy¹⁹², Rita K. Schmutzler^{53, 96, 193}, V. Wendy Setiawan⁹⁷, Kang Shan¹⁹⁴, Weiva Sieh^{195, 196}, 46 Jacques Simard¹⁹⁷, Christian F. Singer¹⁹⁸, Anna P Sokolenko¹¹⁵, Honglin Song¹⁹⁹, Melissa C. 47 Southey^{88, 90, 200}, Helen Steed²⁰¹, Dominique Stoppa-Lyonnet^{50, 202, 203}, Rebecca Sutphen²⁰⁴, 48 Anthony J. Swerdlow^{125, 205}, Yen Yen Tan²⁰⁶, Manuel R. Teixeira^{180, 207}, Soo Hwang Teo^{208, 209}, 49 Kathryn L. Terry^{74, 210}, Mary Beth Terry²¹¹, Mads Thomassen¹⁶⁶, Pamela J. Thompson⁹², Liv 50 Cecilie Vestrheim Thomsen^{26, 27}, Darcy L. Thull²¹², Marc Tischkowitz^{213, 214}, Linda Titus²¹⁵, 51 Amanda E. Toland²¹⁶, Diana Torres^{99, 217}, Britton Trabert²⁸, Ruth Travis²¹⁸, Nadine Tung²¹⁹, 52 Shelley S. Tworoger^{181, 220}, Ellen Valen^{26, 27}, Anne M. van Altena⁴, Annemieke H. van der 53 Hout²²¹, Els Van Nieuwenhuysen¹⁷², Elizabeth J. van Rensburg²²², Ana Vega²²³⁻²²⁵, Digna Velez 54 Edwards²²⁶, Robert A. Vierkant¹⁴⁰, Frances Wang^{227, 228}, Barbara Wappenschmidt^{53, 96}, 55 Penelope M. Webb⁹⁵, Clarice R. Weinberg²²⁹, Jeffrey N. Weitzel²³⁰, Nicolas Wentzensen²⁸, 56 Emily White^{102, 231}, Alice S. Whittemore^{123, 232}, Stacey J. Winham¹⁴⁰, Alicja Wolk^{98, 233}, Yin-Ling 57 Woo²³⁴, Anna H. Wu⁹⁷, Li Yan²³⁵, Drakoulis Yannoukakos²³⁶, Katia M. Zavaglia³⁷, Wei 58 Zheng²¹, Argyrios Ziogas¹⁰, Kristin K. Zorn¹⁴⁷, Douglas Easton^{1,2}, Kate Lawrenson^{3, 237}, Anna 59 DeFazio^{46, 47}, Thomas A. Sellers ²³⁸, Susan J. Ramus^{239, 240}, Celeste L. Pearce^{241, 242}, Alvaro N. 60 Monteiro¹⁸¹, Julie Cunningham²⁴³, Ellen L. Goode²⁴³, Joellen M. Schildkraut²⁴⁴, Andrew 61 Berchuck¹⁸⁶, Georgia Chenevix-Trench¹⁷⁶, Simon A. Gavther³, Antonis C. Antoniou¹, Paul D.P. 62 Pharoah^{1, 2} 63

64

² University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology,
 Cambridge, UK.

 ¹ University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public
 Health and Primary Care, Cambridge, UK.

- ³ Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los
 Angeles, CA, USA.
- ⁴ Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The
 Netherlands.
- ⁵ Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
- ⁶ The Netherlands Cancer Institute Antoni van Leeuwenhoek hospital, Family Cancer Clinic,
 Amsterdam, The Netherlands.
- ⁷ Veneto Institute of Oncology IOV IRCCS, Immunology and Molecular Oncology Unit,
 Padua, Italy.
- ⁸ Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for
 Cancer Genetics, Toronto, ON, Canada.
- ⁹ University of Toronto, Department of Molecular Genetics, Toronto, ON, Canada.

¹⁰ University of California Irvine, Department of Epidemiology, Genetic Epidemiology
 Research Institute, Irvine, CA, USA.

- ¹¹ N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
- 84 ¹² 'Agii Anargiri' Cancer Hospital, Athens, Greece.
- ¹³ University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology,
 Houston, TX, USA.
- ¹⁴ Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden.
- ¹⁵ Vall d'Hebron Institute of Oncology, Hereditary cancer Genetics Group, Barcelona, Spain.
- ¹⁶ University Hospital of Vall d'Hebron, Department of Medical Oncology, Barcelona, Spain.
- ¹⁷ Rutgers Cancer Institute of New Jersey, Cancer Prevention and Control Program, New
 Brunswick, NJ, USA.
- 92 ¹⁸ Landspitali University Hospital, Department of Pathology, Reykjavik, Iceland.
- 93 ¹⁹ University of Iceland, BMC (Biomedical Centre), Faculty of Medicine, Reykjavik, Iceland.
- ²⁰ University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg,
 Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen,
 Germany.
- ²¹ Vanderbilt University School of Medicine, Division of Epidemiology, Department of
 Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN,
 USA.
- 100 ²² Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.
- ²³ Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme,
 Madrid, Spain.

- ²⁴ Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry
 and Genetics, Ufa, Russia.
- ²⁵ Princess Margaret Hospital, Division of Gynecologic Oncology, University Health Network,
 Toronto, Ontario, Canada.
- ²⁶ Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway.
- ²⁷ University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science,
 Bergen, Norway.
- ²⁸ National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD,
 USA.
- ²⁹ Hannover Medical School, Department of Radiation Oncology, Hannover, Germany.
- ³⁰ Hannover Medical School, Gynaecology Research Unit, Hannover, Germany.
- ³¹ IEO, European Institute of Oncology IRCCS, Division of Cancer Prevention and Genetics,
 Milan, Italy.
- ³² Lund University and Skåne University Hospital, Department of Oncology, Lund, Sweden.
- ³³ Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
- ³⁴ Maria Sklodowska-Curie National Research Institute of Oncology, Department of Pathology
 and Laboratory Diagnostics, Warsaw, Poland.
- ³⁵ University of Helsinki, Department of Pathology, Helsinki University Hospital, Helsinki,
 Finland.
- ³⁶ Huntsman Cancer Institute, Department of Medicine, Salt Lake City, UT, USA.
- ³⁷ University Hospital, SOD Genetica Molecolare, Pisa, Italy.
- ³⁸ Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
- ³⁹ The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne,
 Victoria, Australia.
- ⁴⁰ Roswell Park Cancer Institute, Cancer Pathology & Prevention, Division of Cancer
 Prevention and Population Sciences, Buffalo, NY, USA.
- ⁴¹ Division of Human Genetics, The Ohio State University, Department of Internal Medicine,
 Columbus, OH, USA.
- ⁴² German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg,
 Germany.
- ⁴³ University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, University
 Cancer Center Hamburg (UCCH), Hamburg, Germany.
- ⁴⁴ National Cancer Institute, National Institutes of Health, Department of Health and Human
 Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.

л

- ⁴⁵ Tianjin Medical University Cancer Institute and Hospital, Department of Epidemiology,
 Tianjin, China.
- ⁴⁶ The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical
 Research, Sydney, New South Wales, Australia.
- ⁴⁷ Westmead Hospital, Department of Gynaecological Oncology, Sydney, New South Wales,
 Australia.
- ⁴⁸ Columbia University, Departments of Pediatrics and Medicine, New York, NY, USA.
- ⁴⁹ Ghent University, Centre for Medical Genetics, Gent, Belgium.
- ⁵⁰ INSERM U830, Department of Tumour Biology, Paris, France.
- ⁵¹ Institut Curie, Paris, France.
- ⁵² Mines ParisTech, Fontainebleau, France.

⁵³ Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for
 Familial Breast and Ovarian Cancer, Cologne, Germany.

- ⁵⁴ University of New Mexico, University of New Mexico Health Sciences Center, Albuquerque,
 NM, USA.
- ⁵⁵ Alberta Health Services, Department of Cancer Epidemiology and Prevention Research,
 Calgary, AB, Canada.
- ⁵⁶ Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
- ⁵⁷ Fox Chase Cancer Center, Department of Clinical Genetics, Philadelphia, PA, USA.
- ⁵⁸ Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, New
 York, NY, USA.
- 158 ⁵⁹ Cambridge, Cambridge, UK.
- ⁶⁰ CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Molecular Oncology Laboratory, Madrid, Spain.
- ⁶¹ NorthShore University Health System, Center for Medical Genetics, Evanston, IL, USA.
- 162 ⁶² The University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
- ⁶³ Leiden University Medical Center, Department of Pathology, Leiden, The Netherlands.
- ⁶⁴ Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands.
- ⁶⁵ Vall dHebron Institute of Oncology (VHIO), Oncogenetics Group, Barcelona, Spain.
- 166 ⁶⁶ University Hospital Vall dHebron, Clinical and Molecular Genetics Area, Barcelona, Spain.
- ⁶⁷ Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, CA,
 USA.

5

- ⁶⁸ University of Utah, Huntsman Cancer Institute, Department of Population Health Sciences,
 Salt Lake City, UT, USA.
- ⁶⁹ University of Pennsylvania, Basser Center for BRCA, Abramson Cancer Center,
 Philadelphia, PA, USA.
- ⁷⁰ Ev. Kliniken Essen-Mitte (KEM), Department of Gynecology and Gynecologic Oncology,
 Essen, Germany.
- ⁷¹ Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology and Gynecologic
 Oncology, Wiesbaden, Germany.
- ⁷² Jena University Hospital Friedrich Schiller University, Department of Gynaecology, Jena,
 Germany.
- 179 ⁷³ University of Southampton, Faculty of Medicine, Southampton, UK.
- ⁷⁴ Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA,
 USA.
- ⁷⁵ Brigham and Women's Hospital and Harvard Medical School, Channing Division of Network
 Medicine, Boston, MA, USA.
- ⁷⁶ University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig,
 Germany.
- ⁷⁷ University of Leipzig, LIFE Leipzig Research Centre for Civilization Diseases, Leipzig,
 Germany.
- ⁷⁸ University of Manchester, Manchester Academic Health Science Centre, Division of
 Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine
 and Health, Manchester, UK.
- ⁷⁹ St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic
 Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic
 Medicine, Manchester, UK.
- ⁸⁰ University of California at Los Angeles, David Geffen School of Medicine, Department of
 Medicine Division of Hematology and Oncology, Los Angeles, CA, USA.
- ⁸¹ Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre,
 Department of Surgery and Cancer, London, UK.
- ⁸² Masaryk Memorial Cancer Institute, Department of Cancer Epidemiology and Genetics,
 Brno, Czech Republic.
- ⁸³ Chaim Sheba Medical Center, The Susanne Levy Gertner Oncogenetics Unit, Ramat Gan,
 Israel.
- 202 ⁸⁴ Tel Aviv University, Sackler Faculty of Medicine, Ramat Aviv, Israel.
- ⁸⁵ Jonsson Comprehensive Cancer Centre, UCLA, Schools of Medicine and Public Health,
 Division of Cancer Prevention & Control Research, Los Angeles, CA, USA.

⁸⁶ Dana-Farber Cancer Institute, Cancer Risk and Prevention Clinic, Boston, MA, USA. 205 ⁸⁷ University of Florence, Department of Experimental and Clinical Biomedical Sciences 'Mario 206 Serio', Medical Genetics Unit, Florence, Italy. 207 ⁸⁸ Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, Victoria, Australia. 208 ⁸⁹ The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School 209 of Population and Global Health, Melbourne, Victoria, Australia, 210 ⁹⁰ Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, 211 Clayton, Victoria, Australia. 212 ⁹¹ University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, 213 214 Kansas City, KS, USA. ⁹² Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer 215 Prevention and Genetics Program, Los Angeles, CA, USA. 216 ⁹³ National Cancer Institute, Clinical Genetics Branch, Division of Cancer Epidemiology and 217 Genetics, Bethesda, MD, USA. 218 ⁹⁴ Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland, 219 ⁹⁵ OIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, 220 Queensland, Australia. 221 ⁹⁶ Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for 222 Integrated Oncology (CIO), Cologne, Germany. 223 ⁹⁷ University of Southern California, Department of Preventive Medicine, Keck School of 224 Medicine, Los Angeles, CA, USA. 225 ⁹⁸ Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden. 226 ⁹⁹ German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, 227 228 Germany. ¹⁰⁰ Rigshospitalet, Copenhagen University Hospital, Department of Clinical Genetics, 229 Copenhagen, Denmark. 230 ¹⁰¹ Fred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public 231 232 Health Sciences, Seattle, WA, USA. ¹⁰² University of Washington, Department of Epidemiology, Seattle, WA, USA. 233 ¹⁰³ National University of Singapore and National University Health System, Saw Swee Hock 234 School of Public Health, Singapore, Singapore. 235 ¹⁰⁴ National University Health System, Department of Surgery, Singapore, Singapore. 236 ¹⁰⁵ Humboldt-UniversitŠt zu Berlin, and Berlin Institute of Health, Department for Gynecology 237 with the Center for Oncologic Surgery CharitŽ Campus Virchow-Klinikum, CharitŽ Đ 238 UniversitŠtsmedizin Berlin, corporate member of Freie UniversitŠt Berlin, Berlin, Germany. 239

- ¹⁰⁶ University of Texas MD Anderson Cancer Center, Department of Epidemiology, Houston,
 TX, USA.
- ¹⁰⁷ Danish Cancer Society Research Center, Department of Virus, Lifestyle and Genes,
 Copenhagen, Denmark.
- ¹⁰⁸ University of Copenhagen, Molecular Unit, Department of Pathology, Herlev Hospital,
 Copenhagen, Denmark.
- ¹⁰⁹ University of Copenhagen, Department of Gynaecology, Rigshospitalet, Copenhagen,
 Denmark.
- ¹¹⁰ Roswell Park Cancer Institute, Center For Immunotherapy, Buffalo, NY, USA.
- ¹¹¹ BC Cancer, Vancouver General Hospital, and University of British Columbia, British
 Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver, BC, Canada.
- ¹¹² University of British Columbia, Department of Pathology and Laboratory Medicine,
 Vancouver, BC, Canada.
- ¹¹³ University of British Columbia, Department of Obstetrics and Gynecology, Vancouver, BC,
 Canada.
- 255 ¹¹⁴ BC Cancer Research Centre, Department of Molecular Oncology, Vancouver, BC, Canada.
- 256 ¹¹⁵ N.N. Petrov Institute of Oncology, St. Petersburg, Russia.
- ¹¹⁶ Coordinating center: The Netherlands Cancer Institute, The Hereditary Breast and Ovarian
 Cancer Research Group Netherlands (HEBON), Amsterdam, The Netherlands.
- 259 ¹¹⁷ Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
- ¹¹⁸ Pomeranian Medical University, Independent Laboratory of Molecular Biology and Genetic
 Diagnostics, Szczecin, Poland.
- ¹¹⁹ Peter MacCallum Cancer Center, Parkville Familial Cancer Centre, Melbourne, Victoria,
 Australia.
- ¹²⁰ Vilnius University Hospital Santariskiu Clinics, Hematology, oncology and transfusion
 medicine center, Dept. of Molecular and Regenerative Medicine, Vilnius, Lithuania.
- 266 ¹²¹ State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
- 267 ¹²² Landspitali University Hospital, Department of Oncology, Reykjavik, Iceland.
- ¹²³ Stanford University School of Medicine, Department of Epidemiology & Population Health,
 Stanford, CA, USA.
- ¹²⁴ Stanford Cancer Institute, Stanford University School of Medicine, Department of Medicine,
 Division of Oncology, Stanford, CA, USA.

Q

¹²⁵ The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK.

- ¹²⁶ Seoul National University College of Medicine, Department of Preventive Medicine, Seoul,
 Korea.
- ¹²⁷ Seoul National University Graduate School, Department of Biomedical Sciences, Seoul,
 Korea.
- ¹²⁸ Seoul National University, Cancer Research Institute, Seoul, Korea.
- ¹²⁹ University of California at Los Angeles, David Geffen School of Medicine, Department of
 Obstetrics and Gynecology, Los Angeles, CA, USA.
- ¹³⁰ UC Davis Medical Center, Department of Pathology and Laboratory Medicine, Sacramento,
 CA, USA.
- ¹³¹ Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA.
- 283 ¹³² Saint Petersburg State University, Saint Petersburg, Russia.
- ¹³³ Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology,
 Samsung Medical Center, Seoul, Korea.
- ¹³⁴ City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA.
- ¹³⁵ Cancer Genetics Centre, Hong Kong Hereditary Breast Cancer Family Registry, Happy
 Valley, Hong Kong.
- ¹³⁶ The University of Hong Kong, Department of Surgery, Pok Fu Lam, Hong Kong.
- ¹³⁷ Hong Kong Sanatorium and Hospital, Department of Surgery, Happy Valley, Hong Kong.
- ¹³⁸ VIB Center for Cancer Biology, Leuven, Belgium.
- ¹³⁹ University of Leuven, Laboratory for Translational Genetics, Department of Human
 Genetics, Leuven, Belgium.
- ¹⁴⁰ Mayo Clinic, Department of Health Sciences Research, Division of Biomedical Statistics and
 Informatics, Rochester, MN, USA.
- ¹⁴¹ ONCOBELL-IDIBELL-IGTP, Catalan Institute of Oncology, CIBERONC, Hereditary
 Cancer Program, Barcelona, Spain.
- 298 ¹⁴² BC Cancer, Cancer Control Research, Vancouver, BC, Canada.
- ¹⁴³ Inserm U900, Genetic Epidemiology of Cancer team, Paris, France.
- ¹⁴⁴ NYU Langone Medical Center, Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer
 Center, New York, NY, USA.
- 302 ¹⁴⁵ Genome Institute of Singapore, Human Genetics Division, Singapore, Singapore.

¹⁴⁶ University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology
 and Clinical Cancer Genetics Program, Houston, TX, USA.

- ¹⁴⁷ Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA,
 USA.
- ¹⁴⁸ Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Unit of Medical Genetics,
 Department of Medical Oncology and Hematology, Milan, Italy.
- 309 ¹⁴⁹ Duke University Hospital, Department of Surgery, Durham, NC, USA.
- 310 ¹⁵⁰ University of Hawaii Cancer Center, Cancer Epidemiology Program, Honolulu, HI, USA.
- ¹⁵¹ Aichi Cancer Center Research Institute, Division of Cancer Epidemiology and Prevention,
 Nagoya, Japan.
- ¹⁵² Nagoya University Graduate School of Medicine, Division of Cancer Epidemiology,
 Nagoya, Japan.
- ¹⁵³ Samuel Lunenfeld Research Institute, Public Health Ontario, Toronto, ON, Canada.
- ¹⁵⁴ Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre,
 Department Surgery & Cancer, London, UK.
- 318 ¹⁵⁵ University of Glasgow, Institute of Cancer Sciences, Glasgow, UK.
- ¹⁵⁶ University College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials &
 Methodology, London, UK.
- ¹⁵⁷ Roswell Park Cancer Institute, NRG Oncology, Statistics and Data Management Center,
 Buffalo, NY, USA.
- ¹⁵⁸ Roswell Park Cancer Institute, Division of Cancer Prevention and Control, Buffalo, NY,
 USA.
- ¹⁵⁹ Magee-Womens Research Institute and Hillman Cancer Center, Womens Cancer Research
 Center, Pittsburgh, PA, USA.
- ¹⁶⁰ University of Pittsburgh School of Medicine, Division of Gynecologic Oncology,
 Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA, USA.
- ¹⁶¹ Oregon Health & Science University, Department of Obstetrics and Gynecology, Portland,
 OR, USA.
- ¹⁶² Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.
- ¹⁶³ University of Helsinki, Department of Obstetrics and Gynecology, Helsinki University
 Hospital, Helsinki, Finland.
- ¹⁶⁴ National Cancer Centre, Cancer Genetics Service, Singapore, Singapore.
- ¹⁶⁵ Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore,
 Singapore.
- ¹⁶⁶ Odense University Hospital, Department of Clinical Genetics, Odence C, Denmark.
- 338 ¹⁶⁷ Latvian Biomedical Research and Study Centre, Riga, Latvia.

- ¹⁶⁸ Roswell Park Cancer Institute, Department of Gynecologic Oncology, Buffalo, NY, USA.
- ¹⁶⁹ Memorial Sloan Kettering Cancer Center, Clinical Genetics Research Lab, Department of
 Cancer Biology and Genetics, New York, NY, USA.
- ¹⁷⁰ Memorial Sloan Kettering Cancer Center, Clinical Genetics Service, Department of
 Medicine, New York, NY, USA.
- ¹⁷¹ National Institute of Oncology, Department of Molecular Genetics, Budapest, Hungary.
- ¹⁷² University Hospitals Leuven, Division of Gynecologic Oncology, Department of Obstetrics
 and Gynaecology and Leuven Cancer Institute, Leuven, Belgium.
- ¹⁷³ The University of Chicago, Center for Clinical Cancer Genetics, Chicago, IL, USA.
- ¹⁷⁴ Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics,
 New York, NY, USA.
- 350 ¹⁷⁵ Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
- ¹⁷⁶ QIMR Berghofer Medical Research Institute, Department of Genetics and Computational
 Biology, Brisbane, Queensland, Australia.
- 353 ¹⁷⁷ Aalborg University Hospital, Molecular Diagnostics, Aalborg, Denmark.
- ¹⁷⁸ Aalborg University Hospital, Clinical Cancer Research Center, Aalborg, Denmark.
- 355 ¹⁷⁹ Aalborg University, Department of Clinical Medicine, Aalborg, Denmark.
- ¹⁸⁰ Portuguese Oncology Institute, Department of Genetics, Porto, Portugal.
- ¹⁸¹ Moffitt Cancer Center, Department of Cancer Epidemiology, Tampa, FL, USA.
- ¹⁸² IFOM the FIRC Institute of Molecular Oncology, Genome Diagnostics Program, Milan,
 Italy.
- ¹⁸³ Bashkir State University, Department of Genetics and Fundamental Medicine, Ufa, Russia.
- ¹⁸⁴ Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Unit of Molecular Bases of Genetic
 Risk and Genetic Testing, Department of Research, Milan, Italy.
- 363 ¹⁸⁵ Karolinska Institutet, Clinical Genetics, Stockholm, Sweden.
- ¹⁸⁶ Duke University Hospital, Department of Gynecologic Oncology, Durham, NC, USA.
- ¹⁸⁷ Yale School of Public Health, Chronic Disease Epidemiology, New Haven, CT, USA.
- ¹⁸⁸ Fox Chase Cancer Center, Population Studies Facility, Philadelphia, PA, USA.
- ¹⁸⁹ National Institute of Environmental Health Sciences, NIH, Epidemiology Branch, Research
 Triangle Park, NC, USA.
- 369 ¹⁹⁰ Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, Spain.

- ¹⁹¹ Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela,
 Spain.
- ¹⁹² Centre Hospitalier Universitaire de Québec Université Laval Research Center, Genomics
 Center, Québec City, QC, Canada.
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for
 Molecular Medicine Cologne (CMMC), Cologne, Germany.
- ¹⁹⁴ Hebei Medical University, Fourth Hospital, Department of Obstetrics and Gynaecology,
 Shijiazhuang, China.
- ¹⁹⁵ Icahn School of Medicine at Mount Sinai, Department of Population Health Science and
 Policy, New York, NY, USA.
- ¹⁹⁶ Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences,
 New York, NY, USA.
- ¹⁹⁷ Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Genomic
 Center, Québec City, QC, Canada.
- ¹⁹⁸ Medical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna,
 Austria.
- ¹⁹⁹ University of Cambridge, Department of Public Health and Primary Care, Cambridge, UK.
- ²⁰⁰ The University of Melbourne, Department of Clinical Pathology, Melbourne, Victoria,
 Australia.
- ²⁰¹ Royal Alexandra Hospital, Department of Obstetrics and Gynecology, Division of
 Gynecologic Oncology, Edmonton, Alberta, Canada.
- ²⁰² Institut Curie, Service de Génétique, Paris, France.
- 392 ²⁰³ Université Paris Descartes, Paris, France.
- ²⁰⁴ University of South Florida, Epidemiology Center, College of Medicine, Tampa, FL, USA.
- ²⁰⁵ The Institute of Cancer Research, Division of Breast Cancer Research, London, UK.
- ²⁰⁶ Medical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna,
 Austria.
- ²⁰⁷ University of Porto, Biomedical Sciences Institute (ICBAS), Porto, Portugal.
- ²⁰⁸ Cancer Research Malaysia, Breast Cancer Research Programme, Subang Jaya, Selangor,
 Malaysia.
- ²⁰⁹ University of Malaya, Department of Surgery, Faculty of Medicine, Kuala Lumpur,
 Malaysia.
- ²¹⁰ Brigham and Women's Hospital and Harvard Medical School, Obstetrics and Gynecology
 Epidemiology Center, Boston, MA, USA.

- ²¹¹ Columbia University, Department of Epidemiology, Mailman School of Public Health, New
 York, NY, USA.
- ²¹² Magee-Womens Hospital, University of Pittsburgh School of Medicine, Department of
 Medicine, Pittsburgh, PA, USA.
- 408 ²¹³ McGill University, Program in Cancer Genetics, Departments of Human Genetics and
 409 Oncology, Montréal, QC, Canada.
- 410 ²¹⁴ University of Cambridge, Department of Medical Genetics, Cambridge, UK.
- 411 ²¹⁵ Dartmouth College, Geisel School of Medicine, Hanover, NH, USA.
- ²¹⁶ The Ohio State University, Department of Cancer Biology and Genetics, Columbus, OH,
 USA.
- 414 ²¹⁷ Pontificia Universidad Javeriana, Institute of Human Genetics, Bogota, Colombia.
- 415 ²¹⁸ University of Oxford, Cancer Epidemiology Unit, Oxford, UK.
- ²¹⁹ Beth Israel Deaconess Medical Center, Department of Medical Oncology, Boston, MA,
 USA.
- ²²⁰ Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA,
 USA.
- ²²¹ University Medical Center Groningen, University Groningen, Department of Genetics,
 Groningen, The Netherlands.
- 422 ²²² University of Pretoria, Department of Genetics, Arcadia, South Africa.
- 423 ²²³ Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
- 424 ²²⁴ Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.
- ²²⁵ Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo
 Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
- ²²⁶ Vanderbilt University Medical Center, Division of Quantitative Sciences, Department of
 Obstetrics and Gynecology, Department of Biomedical Sciences, Women's Health Research,
 Nashville, TN, USA.
- 430 ²²⁷ Duke Cancer Institute, Cancer Control and Population Sciences, Durham, NC, USA.
- ²²⁸ Duke University Hospital, Department of Community and Family Medicine, Durham, NC,
 USA.
- ²²⁹ National Institute of Environmental Health Sciences, NIH, Biostatistics and Computational
 Biology Branch, Research Triangle Park, NC, USA.
- 435 ²³⁰ City of Hope, Clinical Cancer Genomics, Duarte, CA, USA.
- 436 ²³¹ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

- 437 ²³² Stanford University School of Medicine, Department of Biomedical Data Science, Stanford,
 438 CA, USA.
- 439 ²³³ Uppsala University, Department of Surgical Sciences, Uppsala, Sweden.
- ²³⁴ University of Malaya, Department of Obstetrics and Gynaecology, University of Malaya
 Medical Centre, Kuala Lumpur, Malaysia.
- ²³⁵ Hebei Medical University, Fourth Hospital, Department of Molecular Biology, Shijiazhuang,
 China.
- ²³⁶ National Centre for Scientific Research 'Demokritos', Molecular Diagnostics Laboratory,
 INRASTES, Athens, Greece.
- ²³⁷ Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, CedarsSinai Medical Centre, Department of Obstetrics and Gynecology, Los Angeles, CA, USA.
- 448 ²³⁸ 1032 Royal Pass Road, Tampa, FL, USA.
- ²³⁹ University of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine,
 Sydney, New South Wales, Australia.
- ²⁴⁰ University of NSW Sydney, Adult Cancer Program, Lowy Cancer Research Centre, Sydney,
 New South Wales, Australia.
- ²⁴¹ University of Michigan School of Public Health, Department of Epidemiology, Ann Arbor,
 MI, USA.
- ²⁴² University of Southern California Norris Comprehensive Cancer Center, Department of
 Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA.
- ²⁴³ Mayo Clinic, Department of Health Science Research, Division of Epidemiology, Rochester,
 MN, USA.
- ²⁴⁴ Emory University, Department of Epidemiology, Rollins School of Public Health, Atlanta,
 GA, USA.
- 461
- 462 *These authors had equal contributions.
- 463 Corresponding Author: pp10001@medschl.cam.ac.uk

464

465 Running Title: Polygenic Risk Modelling for Prediction of Epithelial Ovarian

- 466 Cancer Risk
- 467

468 Abstract

469 Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) 470 471 effects in models could improve predictive performance over standard approaches of 472 PRS construction. Here, we implemented computationally-efficient, penalized, logistic 473 regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, "select and shrink for summary 474 statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk 475 prediction. We developed the models in a dataset consisting of 23,564 non-mucinous 476 EOC cases and 40,138 controls participating in the Ovarian Cancer Association 477 Consortium (OCAC) and validated the best models in three populations of different 478 479 ancestries: prospective data from 198,101 women of European ancestry; 7,669 women of East Asian ancestry; 1,072 women of African ancestry, and in 18,915 BRCA1 and 480 12,337 BRCA2 pathogenic variant carriers of European ancestry. In the external 481 validation data, the model with the strongest association for non-mucinous EOC risk 482 derived from the OCAC model development data was the S4 model (27,240 SNPs) with 483 484 odds ratios (OR) of 1.38(95%CI:1.28–1.48,AUC:0.588) per unit standard deviation, in women of European ancestry; 1.14(95%CI:1.08-1.19,AUC:0.538) in women of East 485 486 Asian ancestry; 1.38(95%CI:1.21-1.58,AUC:0.593) in women of African ancestry; hazard ratios of 1.37(95%CI:1.30-1.44,AUC:0.592) in BRCA1 pathogenic variant 487 488 carriers and 1.51(95%CI:1.36-1.67,AUC:0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have 489 clinical utility in ovarian cancer prevention programs. 490

491

492 INTRODUCTION

493 Rare mutations in known high and moderate penetrance susceptibility genes (BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D and the mis-match repair genes) account 494 495 for about 40 percent of the inherited component of EOC disease risk (1,2). Genome 496 wide association studies (GWAS), reviewed in Kar et. al. and Jones et. al. (1,3), have identified 39 common (minor allele frequency [MAF] > 0.05) susceptibility variants 497 which together explain about 6% of the heritability of EOC. Polygenic risk scores 498 499 (PRS) provide an opportunity for refined risk stratification in the general population as 500 well as in carriers of rare moderate or high risk alleles (4,5).

A PRS is calculated as the weighted sum of the number of risk alleles carried for a 501 502 specified set of genetic variants. The best approach to identify the set of variants and 503 their weights in order to optimize the predictive power of a PRS is unknown. A 504 common approach involves selecting a set of variants that reach a threshold for association based on the p-value for each variant with or without clumping and pruning 505 506 to remove highly correlated variants (6,7). More complex prediction models, based on machine learning approaches that do not assume variant independence have also been 507 508 used to construct PRS for complex traits in humans (8.9). To date, these methods have produced only modest gains in predictive power for highly polygenic phenotypes (8,10). 509 510 Penalized regression approaches such as the lasso, elastic net and the adaptive lasso have also been used for the joint estimation of variant effects using individual level data 511 512 for large data sets (11). While they have the potential advantage of improving performance, the major drawback of these methods is the high computational burden 513 514 required to fit the models (11,12).

515 In this study, we present a novel implementation of computationally-efficient PRS 516 models using two approaches: 1) penalized regression models including the lasso, elastic net and minimax concave penalty, for use when individual genotype data are 517 518 available; and 2) a Bayesian regression model with continuous shrinkage priors on 519 variant effect sizes, for use in broader settings where summary statistics are available, 520 hereafter referred to as the "select and shrink with summary statistics" (S4) method. We compare these models with two commonly used methods, stepwise regression with p-521 522 value thresholding and LDPred.

523 MATERIALS (SUBJECTS) AND METHODS

524 EOC Histotypes

EOC is a highly heterogeneous phenotype with five major histotypes for invasive 525 disease - high-grade serous, low-grade serous, endometrioid, clear cell and mucinous 526 histotype. The mucinous histotype is the least common and its origin is the most 527 controversial with up to 60% of diagnosed cases of mucinous ovarian cancer often 528 529 being misdiagnosed metastasis from non-ovarian sites (13). Recent molecular analyses 530 have concluded that most primary invasive mucinous cases are not extra-ovarian metastases (14). However, accurate diagnosis relies on expert histopathology and 531 532 immuno-histochemical profiling (15), which remains a challenge in clinical practice and can be an issue in different cohorts from different time periods. Therefore, in this study, 533 we performed PRS modelling and association testing for all cases of invasive EOC, 534 535 excluding mucinous cases, hereafter referred to as non-mucinous EOC.

536 Model Development Study Population

537 We used genotype data from 23,564 invasive non-mucinous EOC cases and 40,138 controls with >80% European ancestry from 63 case-control studies included in the 538 539 Ovarian Cancer Association Consortium (OCAC) for model development. The study 540 protocol was approved by the institutional review boards of the Brigham and Women's 541 Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required. The distribution of cases by histotype was high-grade serous 542 (13,609), low-grade serous (2,749), endometrioid (2,877), clear cell (1,427), and others 543 (2,902). All mucinous EOC histotypes (2,587) were excluded. Sample collection, 544 genotyping and quality control have been previously described (16). Genotype data 545 546 were imputed to the Haplotype Reference Consortium reference panel on the Michigan Imputation server, using 470,825 SNPs that passed quality control. Of the 32 million 547 SNPs imputed, 10 million had imputation $r^2 > 0.3$ and were included in this analysis. 548

549

Model Validation Study Population

550 UK Biobank Population

551 We validated the best-fitting PRS models developed in the OCAC data in 657 prevalent 552 and incident cases of invasive EOC (346 serous, 98 endometrioid, 51 clear cell and 162 553 other) and 198,101 female controls of European ancestry from the UK Biobank. As with the model development data, all mucinous histotypes (166) were excluded. Samples 554 555 were genotyped using either the Affymetrix UK BiLEVE Axiom Array or Affymetrix UK Biobank Axiom Array (which share 95% marker content), and then imputed to a 556 combination of the Haplotype Reference Consortium, the 1000Genomes phase 3 and 557 558 the UK10K reference panels (17). We restricted analysis to genetically confirmed

females of European/white British ancestry. We excluded individuals if they were outliers for heterozygosity, had low genotyping call rate <95%, had sex chromosome aneuploidy, or if they were duplicates (cryptic or intended) (16). All SNPs selected in the model development phase were available in the UK Biobank.

563 Non-European Ancestry Population

564 We investigated transferability of the best-fitting PRS models to populations of non-European ancestry using genotype data from females of East Asian and African 565 ancestries that had been genotyped as part of the OCAC OncoArray Project (18,19). 566 567 Women of East Asian ancestry - 2,841 non-mucinous invasive EOC (1,960 high-grade serous, 136 low-grade serous, 400 endometrioid, 271 clear cell, 74 other histotypes) 568 and 4,828 controls - were identified using a criterion of >80% Asian ancestry. This 569 570 group included samples collected from population-based studies in China, Japan, Korea, 571 Malaysia as well as samples from studies conducted in the US, Europe and Australia. Details of these data have been previously described (18). Similarly, women of African 572 573 ancestry - 368 cases of non-mucinous invasive EOC (261 high-grade serous, 35 low-574 grade serous, 47 endometrioid, 7 clear cell, 53 other histoptypes) and 704 controls, mainly from studies conducted in the US, were identified using a criterion of >80%575 576 African ancestry.as described previously (19).

577 BRCA1/BRCA2 Pathogenic Variant Carrier Population

We also assessed the performance of the best-fitting PRS models in women of European ancestry (>80% European ancestry) with the pathogenic *BRCA1* and *BRCA2* variants from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). We used genotype data from 18,915 *BRCA1* (2,053 invasive EOC cases – 712 serous, 115

1۵

endometrioid, 9 clear cell, 1217 unknown/other) and 12,337 *BRCA2* (717 invasive EOC
cases – 26 serous, 4 endometrioid, 1 clear cell, 686 unknown/other) pathogenic variant
carriers from 63 studies contributing to CIMBA for independent model validation.
Details of the study population and sample collection have been described previously
(16). Genotyping, data quality control measures, intercontinental ancestry assessment
and imputation to the HRC reference panel are as described for the OCAC study
population.

589 PRS from Meta-analysis of Summary Statistics

590 We leveraged the increase in sample size resulting from a meta-analysis of EOC risk 591 associations, using both the CIMBA and OCAC data described above, to explore 592 performance of PRS approaches based on summary statistics.

593 Statistical Analysis

594 Polygenic Risk Models

595 For all PRS models, we created scores as linear functions of the allele dosage in the

596 general form $PRS_i = \sum_{j=1}^{p} x_{ij}\beta_j$ where genotypes are denoted as x (taking on the minor

allele dosages of 0, 1 and 2), with x_{ij} representing the *i*th individual for the *j*th SNP

(out of p SNPs) on an additive log scale and β_i represents the weight - the log of the

- odds ratio of the *j*th SNP. We used different approaches to select and derive the
- 600 optimal weights, β_i , in models as described below.

601 *Penalized logistic regression models: the lasso, elastic net and minimax concave* 602 *penalty*

A penalized logistic regression model for a set of SNPs aims to identify a set of
 regression coefficients that minimize the regularized loss function given by

$$plr(x;\lambda,\kappa) = \begin{cases} x - \lambda sign(x)/(1-\kappa) & if |x| < \lambda/\kappa \text{ and } |(x)| > \lambda \\ x & if |x| \ge \frac{\lambda}{\kappa} \\ 0 & if |(x)| < \lambda \end{cases}$$

where x is the effect estimate of a SNP, λ is the tuning parameter and κ is the threshold (penalty) for different regularization paths. λ and κ are parameters that need to be chosen during model development to optimize performance. The lasso, elastic net, minimax concave penalty (MCP), and p-value thresholds are instances of the function with different κ values. We minimized the winner's curse effect on inflated effect estimates for rare SNPs by penalizing rarer SNPs more heavily than common SNPs. Details are provided in the Supplementary Methods.

612 We used a two-stage approach to reduce computational burden without a corresponding loss in predictive power. The first stage was a SNP selection stage using a sliding 613 windows approach, with 5.5Mb data blocks and a 500kb overlap between blocks. SNP 614 615 selection was performed for each block and selected SNPs were collated. Single SNP association analyses were then run, and all SNPs with a χ^2 test statistic of less than 2.25 616 were excluded. Penalized regression models were applied to the remaining SNPs 617 using λ values of 3.0 and κ values of 0.0, 0.2, 0.4, 0.6, 0.8 and 1.0. SNPs selected in any 618 of these models were included in subsequent analyses. 619

In the second stage, we fit penalized regression models to the training dataset with λ values ranging from 3.0 to 5.5 in increments of 0.1 iterated over κ values from -3.0 to 1 in increments of 0.1. The lasso model ($\kappa = 0$) for each value of λ was fitted first, to obtain a unique maximum. From the fitted maximum the κ value was changed, and the model refitted.

We applied this two-stage approach with five-fold cross-validation (**Figure 1**). The variants and their weights from the two-stage penalized logistic regression modelling in the training data were used to calculate the area under the receiver operating characteristic curve (AUC) in the test data. We repeated this process for each crossvalidation iteration to obtain a mean AUC for each combination of λ and κ :

Finally, we selected the tuning and threshold parameters from the lasso, elastic net and minimax concave penalty models with the maximum mean cross-validated AUC and fitted penalized logistic regression models with these parameters to the entire OCAC dataset to obtain SNP weights for PRS scores.

634 Stepwise logistic regression with variable P-value threshold

This model is a general PLR model with κ =1. As with the other PLR models, we investigated various values for λ values (corresponding to a variable P-value threshold for including a SNP in the model). However, we observed that the implementation of this model on individual level data was more difficult than for other κ values because the model would sometimes converge to a local optimum rather than the global optimum. Therefore, we applied an approximate conditional and joint association analysis using summary level statistics correcting for estimated LD between SNPs,

using a reference panel of 5,000 individual level genotype OCAC data as described in
Yang et.al (20). Details are provided in the Supplementary Methods.

644 *LDPred*

645 LDPred is a Bayesian approach that adjusts GWAS summary statistics for the effects of 646 LD by shrinking the posterior mean effect size of each genetic marker based on a point-647 normal prior on the effect sizes and LD information from an external reference panel. We derived seven candidate polygenic risk scores assuming the fractions of associated 648 variants were 0.001, 0.003, 0.01, 0.03, 0.1, 0.3 and 1.0 respectively (21) using an LD 649 650 reference panel of 503 samples of European ancestries from the 1000 Genomes phase 3 651 release and effect estimates from the genome wide association analysis on the OCAC 652 model development data.

653 Select and shrink using summary statistics (S4)

654 The S4 algorithm is similar to the PRS-CS algorithm (22) which is a Bayesian approach 655 that uses summary statistics and between-SNP correlation data from a reference panel to generate the PRS scores by placing a continuous shrinkage prior on effect sizes. We 656 657 adapted this method with penalization of rarer SNPs by correcting for the standard 658 deviation resulting in the selection of fewer SNPs. To implement this algorithm, we 659 varied three parameters, a, b, ϕ , which together control the degree of shrinkage of effect estimates. Φ , the overall shrinkage parameter, is influenced by values of a which 660 661 control shrinkage of effect estimates around 0 and b which control shrinkage of larger effect estimates. Smaller values of *a* result in more severe shrinkage of effect estimates 662 than larger values. Conversely, smaller values of b produce less severe shrinkage than 663 664 larger values.

We generated summary statistics for each cross-validation training set and selected the parameters that gave the best results on average from the cross-validation and applied these to the set of summary statistics for the complete OCAC data set to obtain the final set of weights.

669 **PRS based on meta-analysis of OCAC-CIMBA summary statistics**

670 We conducted a meta-analysis of the EOC associations in BRCA1 variant carriers, 671 BRCA2 variant carriers and the participants participating in OCAC using previously described methodological approaches (16). Additional details are provided in the 672 673 Supplementary Methods. We constructed two PRS models using results from the 674 OCAC-CIMBA meta-analysis: the Select and Shrink (OCAC-CIMBA) PRS and the Stepwise (OCAC-CIMBA) PRS. To construct the Select and Shrink (OCAC-CIMBA) 675 676 PRS, we applied the a, b and φ parameters from the Select and Shrink model described above to the summary statistics from the meta-analysis to obtain a different set of SNPs 677 678 and weights. We generated the Stepwise (OCAC-CIMBA) PRS by using histotype-679 specific results from the meta-analysis. We selected all SNPs that were genome-wide significant at nominal thresholds ($p < 5x10^{-8}$), along with any independent signals in the 680 same region with $p < 10^{-5}$ from the histotype specific analyses for low-grade serous, 681 high-grade serous, endometrioid, clear cell ovarian cancer and non-mucinous invasive 682 683 EOC.

684 Polygenic risk score performance.

The best lasso, elastic net, stepwise and S4 models from the model development stage were validated using two independent data sources: the UK Biobank data and *BRCA1/BRCA2* pathogenic variant carriers from the CIMBA. In the UK Biobank data,

688 we evaluated discriminatory performance of the models using the AUC and examined 689 the association between standardized PRS and risk of non-mucinous EOC using 690 logistic regression analysis. For the CIMBA data, we assessed associations for each 691 version of the PRS and invasive non-mucinous EOC risk using weighted Cox regression 692 methods previously described (5). PRSs in the CIMBA data were scaled to the same 693 PRS standard deviations as the OCAC data, meaning that per standard deviation hazard ratios estimated on CIMBA data are comparable to PRS associations in the OCAC and 694 695 UK Biobank data. The regression models were adjusted for birth cohort (<1920, 1920-696 1929, 1930-1939, 1940-1949, \geq 1950) and the first four ancestry informative principal 697 components (calculated separately by iCOGS/OncoArray genotyping array) and stratified by Ashkenazi Jewish ancestry and country. Absolute risks by PRS percentiles 698 699 adjusting for competing risks of mortality from other causes were calculated as described in the Supplementary Material. 700

701 Transferability of PRS scores to non-European Ancestry

We implemented two straightforward approaches to disentangle the role of ancestry on polygenic risk scoring. We selected homogenous ancestral samples by using a high cutoff criterion of 80% ancestry and we standardized the polygenic risk scores by meancentering within each population. These approaches led to a more uniform distribution of polygenic risk scores within each ancestral population. Further adjustments using principal components of ancestry did not attenuate risk estimates.

708 Data Availability

OncoArray germline genotype data for the OCAC studies have been deposited at the
European Genome-phenome Archive (EGA; https://ega-archive.org/), which is hosted

711 by the EBI and the CRG, under accession EGAS00001002305. Summary results are available from the Ovarian Cancer Association Consortium 712 713 (http://ocac.ccge.medschl.cam.ac.uk/). A subset of the OncoArray germline genotype 714 data for the CIMBA studies will be made publically available through the database of 715 Genotypes and Phenotypes (dbGaP) under accession phs001321.v1.p1. The complete 716 data set will not be made publically available because of restraints imposed by the ethics committees of individual studies; requests for further data can be made to the Data 717 718 Access Coordination Committee (http://cimba.ccge.medschl.cam.ac.uk/)

719 Ethics Statement

All study participants provided written informed consent and participated in research or

721 clinical studies at the host institute under ethically approved protocols. The studies and

their approving institutes are listed in the Supplementary Material (Ethics Statement)

723 **Results**

724 Model development

725 For models based on individual level genotype data, the elastic net model had the best 726 predictive accuracy (model parameters: $\lambda = 3.3$, $\kappa = -2.2$, AUC=0.586) Predictive accuracy 727 for the lasso model (λ =3.3, AUC= 0.583) was slightly lower (**Table 1**). The optimal 728 value of λ obtained from regularization paths for the MCP model was 3.3. Further 729 reductions in the degree of penalization for the MCP models did not improve prediction 730 accuracy. Therefore, the best MCP model was equivalent to the lasso model. For models based on summary statistics, the best-fitting S4 model had the best performance 731 (a=2.75, b=2, φ =3e-6, AUC=0.593), whereas the best LDPred model had the poorest 732

733	performance of the methods tested (ρ =0.001, AUC=0.552). The mean odds ratios per
734	standard deviation are shown in Table 1 along with the number of SNPs included in the
735	final model when the models were built with the relevant parameters using the complete
736	dataset. All SNPs selected and the associated weights for each model are provided in
737	Supplementary Tables $1 - 6$. Given the poorer performance of the LDpred model and
738	the very large number of SNPs included in the final model it was not considered for
739	further validation in other datasets.

AUC 95% CI Model Number of Tuning parameter for OR per 1 best performance SD of PRS SNPs* Models based on individual level genotype data a) Lasso 1,403 λ=3.3 0.583 1.35 1.30 - 1.39Elastic net 10,797 λ=3.3, κ=-2.2 0.586 1.36 1.31 - 1.40MCP 1,403 λ=3.3 0.583 1.35 1.30 - 1.39b) Models based on summary statistics LDPred 5,291,719 $\rho = 0.001$ 0.552 1.21 1.13 - 1.29Stepwise 22 λ=5.4 0.572 1.30 1.26 - 1.34Select and Shrink (OCAC) 27,240 a=2.75, b=2, o=3e-6 0.593 1.39 1.34 - 1.44

740 Table 1: Performance of different PRS models in five-fold cross validation of OCAC data

Abbreviations: AUC-Area Under the Receiver Operating Characteristic (ROC) Curve AUC); OR-Odds Ratio; SD-Standard deviation; PRS-Polygenic Risk Score; CI-Confidence Interval. NA-Not Applicable.

* Number of SNPs in PRS model run on full OCAC data set after selection of model parameters

741 Model validation in women of European ancestry: general population (UK Biobank)

742 and BRCA1/BRCA2 pathogenic variant carriers (CIMBA)

The best AUC estimates derived from cross-validation are likely to be upwardly biased due to overfitting. Therefore, we used the UK Biobank data as an external validation dataset. Overall the PLR models performed slightly better in the UK Biobank data than the model development data (**Table 2**). Of the models developed using the OCAC model development data, the association between PRS and non-mucinous EOC was strongest with the Select and Shrink derived PRS (OR per unit SD=1.38, 95%CI:1.28– 1.48) and slightly lower for the lasso PRS (OR per unit SD=1.37, 95%CI:1.27–1.48),

750	the elastic net PRS (OR per unit SD=1.36, 95%CI:1.26–1.47) and the stepwise PRS
751	model (OR per unit SD=1.35, 95%CI:1.26-1.46). In BRCA1 and BRCA2 variant
752	carriers, prediction accuracy was generally higher among BRCA2 carriers than BRCA1
753	carriers. Consistent with results from the general population in the UK Biobank, the
754	Select and Shrink PRS model also had the strongest association and predictive accuracy
755	for invasive EOC risk in both BRCA1 (HR per unit SD=1.37, 95%CI:1.30-1.44,
756	AUC=0.592) carriers and BRCA2 carriers (HR per unit SD=1.51, 95%CI:1.36-1.67,
757	AUC=0.624). The PRS models developed using the OCAC-CIMBA meta-analysis
758	results had better discriminative ability in the UK Biobank than the PRS models
759	developed using only OCAC data. Compared with the Select and Shrink model using
760	only OCAC data, the Select and Shrink PRS model derived from the meta-analysis had
761	fewer SNPs (n=18,007), a stronger association with invasive EOC risk (OR per unit
762	SD=1.42, 95%CI:1.32–1.54) and better predictive accuracy (AUC=0.596). Similarly,
763	the Stepwise model from the OCAC-CIMBA meta-analysis performed better than the
764	Stepwise model from only OCAC data (OR per unit SD=1.39, 95%CI:1.29-1.50,
765	AUC=0.595), but included more SNPs (n=36)

Table 2: External validation of PRS models in European populations using data from UK Biobank and CIMBA

	SNPs		UK Bio	bank	CIMI	BA BRCA	1 carriers [†]	CIMBA BRCA2 carriers†			
Model (data set)		AUC	OR	95% CI	AUC	HR	95% CI	AUC	HR	95% CI	
a) PRS models based on OCAC data											
Lasso (OCAC)	1,403	0.587	1.37	1.27 - 1.48	0.573	1.29	1.23 – 1.36	0.627	1.49	1.34 – 1.65	
Elastic net (OCAC)	10,797	0.588	1.36	1.26 – 1.47	0.583	1.34	1.27 – 1.41	0.617	1.50	1.35 – 1.66	
Stepwise (OCAC)	22	0.588	1.35	1.26 - 1.46	0.563	1.22	1.17 - 1.28	0.605	1.40	1.26 - 1.55	
Select and shrink (OCAC)	27,240	0.588	1.38	1.28 - 1.48	0.592	1.37	1.30 - 1.44	0.624	1.51	1.36 – 1.67	
b) PRS models based on meta-analysis of OCAC and CIMBA data											
Stepwise (OCAC-	36	0.595	1.39	1.29 - 1.50							

CIMBA)*						
Select and shrink (OCAC-CIMBA)	18,007	0.596	1.42 1.32 – 1.54			

Abbreviations: AUC-Area Under the Receiver Operating Characteristic Curve; OR-Odds Ratio; HR-Hazards ratio

*results in CIMBA are overfitted as the CIMBA data was used for model development

† HR are adjusted for birth cohort and the first four ancestry informative principal components. AUC were estimated from models fitting only the PRS as the independent variable.

768

769	Compared with women in the middle quintile, women in the top 95 th percentile of the							
770	lasso derived PRS model had 2.23-fold increased odds of non-mucinous EOC (Table							
771	3). The observed distribution of the OR estimates was consistent with ORs obtained							
772	from theoretical predicted values under the assumption that all SNPs interact							
773	multiplicatively, especially for the lasso model (Figure 3), with all 95% confidence							
774	intervals intersecting with the theoretical estimates for women of European ancestry.							

		UK Bioba	ank		East	Asian	African			
Percent	ile Controls	Cases (n)	OR (95% CI)	Controls (n)	Cases (n) OR (95% CI)	Controls	Cases	OR (95% CI)	
	(n)						(n)	(n)		
a.	Lasso									
0-5	9880	12	0.42 (0.22 - 0.72)	278	106	0.65 (0.51 – 0.83)	35	19	0.89 (0.47 – 1.65)	
5-10	9870	24	0.83 (0.52 – 1.27)	271	112	0.71 (0.55 – 0.90)	41	13	0.52 (0.25 – 1.01)	
10-20	19733	53	0.92 (0.66 - 1.27)	487	280	0.98 (0.82 – 1.18)	81	26	0.53 (0.31 – 0.88)	
20-40	39468	104	0.90 (0.69 – 1.18)	993	541	0.93 (0.80 – 1.08)	154	60	0.64 (0.42 - 0.99)	
40-60	39457	115	1.00	967	566	1.00	133	81	1.00	
60-80	39425	147	1.28 (1.00 – 1.64)	941	593	1.08 (0.93 – 1.25)	136	78	0.94 (0.64 - 1.39)	
80-90	19699	87	1.52 (1.14 – 2.00)	466	301	1.10 (0.92 – 1.32)	63	44	1.15 (0.71 – 1.84)	
90-95	9842	51	1.78 (1.27 – 2.46)	214	169	1.35 (1.07 – 1.69)	34	20	0.97 (0.51 – 1.78)	
95-100	9830	64	2.23 (1.64 – 3.02)	211	173	1.40 (1.12 – 1.76)	27	27	1.64 (0.90 – 3.00)	
b.	Elastic Net									
0-5	9876	17	0.67 (0.39 – 1.09)	277	107	0.72 (0.56 – 0.92)	35	19	0.90 (0.47 – 1.64)	
5-10	9876	17	0.67 (0.39 – 1.09)	271	112	0.78 (0.61 – 0.99)	41	13	0.52 (0.25 – 1.01)	
10-20	19740	45	0.89 (0.62 - 1.26)	497	270	1.02 (0.85 – 1.22)	81	26	0.53 (0.31 – 0.88)	
20-40	39453	120	1.19 (0.91 – 1.55)	967	567	1.10 (0.95 – 1.28)	154	60	0.64 (0.42 - 0.96)	
40-60	39471	101	1.00	1000	533	1.00	133	81	1.00	
60-80	39413	159	1.58 (1.23 – 2.03)	926	608	1.23 (1.06 – 1.43)	136	78	0.94 (0.64 – 1.39)	
80-90	19695	91	1.80 (1.36 – 2.40)	457	310	1.27 (1.06 – 1.52)	63	44	1.15 (0.71 – 1.84)	
90-95	9841	52	2.07 (1.47 – 2.87)	226	157	1.30 (1.04 – 1.64)	34	20	0.97 (0.51 – 1.78)	
95-100	9839	55	2.18 (1.56 – 3.02)	207	177	1.60 (1.28 – 2.01)	27	27	1.64 (0.90 – 3.00)	
C.	Stepwise									
0-5	9880	13	0.39 (0.21 – 0.67)	254	130	0.90 (0.71 – 1.14)	40	14	0.75 (0.37 – 1.44)	

Table 3: Association between polygenic risk scores and non-mucinous EOC by PRS percentiles and ancestry

UK Biobank				Asian	African				
Percentile	Controls	Cases (n)	OR (95% CI)	Controls (n)	Cases (r) OR (95% CI)	Controls	Cases	OR (95% CI)
	(n)						(n)	(n)	
5-10	9874	19	0.57 (0.34 – 0.91)	268	115	0.76 (0.59 – 0.96)	43	11	0.55 (0.26 – 1.10)
10-20	19742	44	0.67 (0.47 – 0.93)	494	273	0.98 (0.81 – 1.17)	80	27	0.72 (0.42 – 1.21)
20-40	39470	102	0.77 (0.60 - 1.00)	970	564	1.03 (0.89 – 1.19)	142	72	1.09 (0.73 – 1.63)
40-60	39440	132	1.00	979	564	1.00	146	68	1.00
60-80	39414	158	1.20 (0.95 – 1.51)	951	583	1.08 (0.94 – 1.25)	130	84	1.39 (0.93 – 2.07)
80-90	19697	88	1.33 (1.02 – 1.75)	456	311	1.21 (1.01 – 1.44)	61	46	1.62 (1.00 – 2.61)
90-95	9853	41	1.24 (0.86 – 1.75)	236	147	1.10 (0.87 – 1.38)	35	19	1.17 (0.61 – 2.17)
95-100	9834	60	1.82 (1.33 – 2.46)	220	164	1.32 (1.04 – 1.65)	27	27	2.15 (1.17 – 3.95)
d. Se	elect and Shrir	nk							
0-5	9957	16	0.54 (0.31 – 0.89)	279	105	0.63 (0.49 – 0.81)	38	16	0.71 (0.36 – 1.33)
5-10	9888	15	0.51 (0.29 – 0.85)	254	129	0.85 (0.67- 1.08)	41	13	0.53 (0.26 – 1.03)
10-20	19812	51	0.87 (0.62 – 1.20)	489	278	0.96 (0.80-1.14)	81	26	0.54 (0.32 – 0.90)
20-40	39435	113	0.97 (0.75 – 1.25)	1013	521	0.86 (0.75 – 1.00)	156	58	0.62 (0.41 – 0.94)
40-60	39512	117	1.00	961	572	1.00	134	80	1.00
60-80	39316	158	1.36 (1.07 – 1.73)	950	584	1.03 (0.89 – 1.20)	137	77	0.94 (0.63 – 1.40)
80-90	19718	77	1.32 (0.98 – 1.76)	434	333	1.29 (1.08 – 1.54)	61	46	1.26 (0.79 – 2.02)
90-95	9791	45	1.55 (1.09 – 2.17)	233	150	1.08 (0.86 – 1.36)	30	24	1.34 (0.73 – 2.45)
95-100	9775	65	2.25 (1.65 – 3.03)	215	169	1.32 (1.05 – 1.66)	26	28	1.80 (0.99 – 3.31)

OR: Odds Ratio; CI: Confidence Interval.

389 Absolute Risk of Developing Ovarian Cancer by PRS percentiles

We estimated cumulative risk of EOC experienced between birth and the age of 80 within PRS percentiles for women in the general population (**Figure 2**), by applying the odds ratio from the PRS models to age-specific population incidence and mortality data for England in 2016. For *BRCA1* and *BRCA2* pathogenic variant carriers, we applied the estimated hazard ratios from PRS models to age-specific incidence rates obtained from Kuchenbaecker et al. (23).

For women in the general population, the estimated cumulative risks of EOC by age 80 for women at the 99th centile of the PRS distribution were 2.24%, 2.18%, 2.54% and 2.81% for the lasso, elastic net, stepwise and S4 models, respectively. In comparison, the absolute risks of EOC by age 80 for women at the 1st centile were 0.76%, 0.78%, 0.64% and 0.56% for the lasso, elastic net, stepwise and S4 models, respectively.

401 The absolute risks of developing EOC in BRCA1 and BRCA2 pathogenic variant carriers 402 were considerably higher than for women in the general population (Figures S1:Cumulative 403 risk of ovarian cancer risk in *BRCA1* carriers by polygenic risk score percentiles and S2: 404 Cummulative risk of ovarian cancer risk in BRCA2 carriers by polygenic risk score 405 percentiles). The estimated absolute risk of developing ovarian cancer by age 80 for BRCA1 carriers at the 99th PRS centiles were 63.2%, 66.3%, 59.0% and 68.4% for the lasso, elastic 406 407 net, stepwise and S4 models, respectively. The corresponding absolute risks for women at the 1st PRS centile were 27.7%, 25.6%, 30.8% and 24.2%. Absolute risks of developing EOC 408 409 were lower for BRCA2 carriers than BRCA1 carriers, with absolute risks for women in the 99th centile being 36.3%, 36.3%, 33.0% and 36.9%; and absolute risks for women in the 1st 410 centile being 7.10%, 7.12%, 8.24% and 6.92% for the lasso, elastic net, stepwise and S4 411

412 models, respectively. Absolute risks for *BRCA1* and *BRCA2* carriers at the 10th and 90th
413 percentile are provided in Supplementary Table 7.

414

415 **PRS distribution and ancestry**

416 To investigate the transferability of the PLR derived PRS to other populations, we applied the 417 scores to women of African (N=1,072) and Asian (N=7,669) ancestry genotyped as part of 418 the OncoArray project. In general, the distributions of the raw polygenic scores were 419 dependent on both the statistical methods used in SNP selection and ancestral group. PRS 420 models that included more variants had less dispersion, such that the elastic net models had 421 the least between individual variation in all ancestral groups (standard deviation=0.15, 0.19) 422 and 0.22 for individuals of Asian, African and European ancestries respectively), while the 423 distributions from the stepwise models were the most dispersed (standard deviation = 0.23, 424 0.27 and 0.30 for individuals of Asian, African and European ancestries respectively). As 425 expected, given the variation in variant frequencies by population, the distribution of 426 polygenic scores was significantly different across the three ancestral groups, with the least 427 dispersion among women of Asian ancestry and the most variation in women of European 428 ancestry. The difference in polygenic risk score distribution was minimized after correction 429 for ancestry by standardizing the PRS to have unit standard deviation using the control 430 subjects for each ancestral group. For comparison, we investigated the use of the first 20 431 principal components to correct for ancestry and we obtained similar results.

High PRSs were significantly associated with risk of non-mucinous EOC in both Asian and
African ancestries (**Table 4**), although the effects were weaker than in women of European
ancestry. For example, with the lasso model, the odds ratio (95% CI) per unit standard
deviation increment in polygenic score was estimated to be 1.16 (1.11–1.22) in women of

436	East Asian ancestry and 1.28 (1.13–1.45) in women of African ancestry compared to 1.37
437	(1.27-1.48) in women of European ancestry (p for heterogeneity < 0.0001). Variability in
438	effect sizes among ancestral groups was highest for the stepwise model ($I^2 = 92\%$) versus
439	84% and 83% for elastic net and lasso derived polygenic scores respectively. The best
440	discriminative model among women of East Asian and African ancestry were the Elastic net
441	PRS (AUC=0.543) and the Select and Shrink PRS model derived from OCAC-CIMBA meta-
442	analysis (AUC=0.596) respectively. Women of African ancestry in the top 5% of the PRS
443	had about two-fold increased risk compared to women in the middle quintile (lasso
444	OR:1.64,95%CI: 0.90-3.00; elastic net OR:1.64,95%CI:0.90-3.00; stepwise OR:2.15,
445	95%CI:1.17-3.95; S4 OR:1.80, 95%CI:0.99-3.31). Effect estimates were smaller in women
446	of East Asian ancestry with women in the top 5% of the PRS, having about a 1.5 fold
447	increased risk compared to women in the middle quintile (lasso OR:1.40, 95%CI:1.12-1.76;
448	elastic net OR:1.60, 95% CI:1.28-2.01; stepwise OR:1.32, 95%CI:1.04-1.65; S4 OR:1.32,
449	95%CI:1.05–1.66).

450	Table 4:	External	validation	of PRS	models i	n East	Asian and	l African	Populations
									-

Madal	Ea	st Asian	ancestries	African ancestries			
Model	AUC OR 95% CI		AUC	OR	95% CI		
Lasso	0.541	1.16	(1.11 – 1.22)	0.576	1.28	(1.13 – 1.45)	
Elastic net	0.543	1.17	(1.12 – 1.23)	0.574	1.29	(1.14 – 1.47)	
Stepwise (OCAC)	0.528	1.11	(1.06 – 1.16)	0.581	1.34	(1.18 – 1.52)	
Select and shrink (OCAC)	0.538	1.14	(1.08 - 1.19)	0.593	1.38	(1.21 – 1.58)	
Stepwise (OCAC-CIMBA)	0.542	1.17	(1.11 – 1.23)	0.594	1.37	(1.20 – 1.56)	
Select and shrink (OCAC-CIMBA)	0.537	1.14	(1.08 – 1.19)	0.596	1.41	(1.23 – 1.61)	

452 **Discussion**

453 Genetic risk profiling with polygenic risk scores has led to actionable outcomes for cancers 454 such as breast and prostate (24,25). Previous PRS scores for invasive EOC risk in the general 455 population and BRCA1/BRCA2 pathogenic variant carriers have been based on genetic 456 variants for which an association with EOC risk had been established at nominal genome-457 wide significance (4,5,26-28). Here, we explored the predictive performance of 458 computationally-efficient, penalized, regression methods in modelling joint SNP effects for 459 EOC risk prediction in diverse populations and compared them with common approaches. By 460 leveraging the correlation between SNPs which do not reach nominal genome-wide 461 thresholds and including them in PRS models, the polygenic risk scores derived from 462 penalized regression models in this analysis provide stronger evidence of association with 463 risk of non-mucinous EOC than previously published PRSs in both the general population 464 and in BRCA1/BRCA2 pathogenic variant carriers.

465 Recently, Barnes et. al derived a PRS score using 22 SNPs that were significantly associated 466 with high-grade serous EOC risk in GWAS (PRS_{HGS}) to predict EOC risk in BRCA1/BRCA2 467 pathogenic variant carriers (5). To make effect estimates obtained in this analysis comparable 468 to the effect estimates obtained from the PRS_{HGS}, we standardized all PRSs using the 469 standard deviation from unaffected BRCA1/BRCA2 carriers; all PRS models in this analysis 470 except the Stepwise (OCAC only) had higher effect estimates (5). However, the 471 corresponding AUCs were higher for the PRS_{HGS} model (0.604 for BRCA1 carriers and 0.667 472 for BRCA2 carriers), most likely as a result of inclusion of other predictors (birth cohort and 473 principal components) in the model. The AUC estimates for women in the general 474 population, as estimated from the UK Biobank, are slightly higher than estimates from

475 previously published PRS models for overall EOC risk by Wei et al (AUC=0.57) and Yang et
476 al (AUC=0.58) (26,28)

477 In theory, polygenic risk profiling has the potential for clinical utility, being the earliest 478 measurable contributor to risk which may lead to actionable outcomes. The level of risk among women considered to have a high polygenic risk score, for example women in the 95th 479 480 percentile, for all of the models we considered approaches the same level of risk conferred by 481 pathogenic variants in moderate penetrance genes such as FANCM (RR=2.1, 95%CI=1.1-482 3.9) and PALB2 (RR=2.91 95%CI=1.40-6.04) (29,30). The inclusion of other risk factors 483 such as family history of ovarian cancer, presence of rare pathogenic variants, age at 484 menarche, oral contraceptive use, hormone replacement therapy, parity, and endometriosis in 485 combination with the PRS models could potentially improve risk stratification as has been 486 implemented in the CanRisk tool (www.canrisk.org), which currently uses a PRS model 487 based on 36 SNPs with the potential to use other PRS models (31,32).

488 An important consideration in the clinical utility of polygenic risk scores is the degree to 489 which results are applicable to diverse populations. We found that the discriminative ability 490 varied substantially by ancestral group. As expected, given that the model development 491 dataset consisted entirely of women of European ancestry, the models had greater 492 discriminative power in women of European ancestry, relative to women of African and East 493 Asian ancestry. We observed greater attenuation of discriminative ability in East Asian 494 populations than African populations. This finding is in contrast to what one would expect 495 given human demographic history, and results from genome wide association studies for 496 EOC (18,19,33,34). One possible explanation for this disparity is the small sample size and 497 imprecise effect estimates for women of African ancestry in this study, due to the larger 498 differences in allele frequency between this population and that of the cohort used to develop

the model. Although the model development data for this analysis was predominantly women of European ancestry, the models developed using our approach performed substantially better in women of African ancestry than a PRS model developed by combining 24 published GWAS SNPS associated with non-mucinous EOC, for which the odds of EOC risk was 1.20 fold per standard deviation of PRS (19).

504 Further refinements to our models, by exploring other penalty functions, may improve the 505 predictive value of the PRS. However, this approach may be complicated by difficulties that 506 arise due to the correlation structure between SNPs. Another option to optimizing the models 507 could be varying the penalization function based on prior knowledge. In genomic regions that 508 are known to have variants associated with EOC, one is more likely to find other risk-509 associated variants. Therefore, varying the penalty function in these regions such that more 510 SNPs are selected into the model may improve the PRS. Finally, as more functional data 511 become available, modifying penalty functions to incorporate functional data may further 512 improve the PRS. Current approaches for incorporating functional annotation have resulted in 513 only modest gains in prediction accuracy for complex traits such as breast cancer, celiac 514 disease, type 2 diabetes and rheumatoid arthritis, much of which is attributed to the SNPs 515 selected in the models and not the functional annotation (35).

The UK Biobank, our model validation dataset for women in the general population, had a small number of invasive EOC cases with a disproportionately high number of mucinous cases (166 of the 823 invasive EOC cases or ~20%). Furthermore, cases of the serous histotype could not be classified as either high-grade or low-grade. Therefore, we could not investigate EOC histotype-specific polygenic scores. As the serous histotype is the most common, it is possible that a high-grade serous EOC specific polygenic score may have better predictive value than a non-mucinous polygenic score.

523 Conclusion

524 In conclusion, our results indicate that using the lasso model for individual level genotype 525 data and the S4 model for summary level data in polygenic risk score construction provide an 526 improvement in risk prediction for non-mucinous EOC over more common approaches. Our 527 approach overcomes the computational limitations in the use of penalized methods for large 528 scale genetic data, particularly in the presence of highly-correlated SNPs and the use of cross-529 validation for parameter estimation is preferred. In practical terms, the polygenic risk score 530 provides sufficient discrimination, particularly for women of European ancestry, to be 531 considered for inclusion in risk prediction and prevention approaches for EOC in the future. 532 Further studies are required to optimize these polygenic risk scores in ancestrally diverse 533 populations and to validate their performance with the inclusion of other genetic and lifestyle 534 risk factors.

535 Acknowledgements and Funding

536 Full acknowledgement and funding details are provided in the Supplementary Material

537

538 **Conflicts of Interest**

Anna DeFazio has received a research grant from AstraZeneca, not directly related to the content of this manuscript. Matthias W. Beckmann conducts research funded by Amgen, Novartis and Pfizer. Peter A. Fashing conducts research funded by Amgen, Novartis and Pfizer. He received Honoraria from Roche, Novartis and Pfizer. Allison W. Kurian reports research funding to her institution from Myriad Genetics for an unrelated project. Usha Menon owns stocks in Abcodia Ltd. Rachel A. Murphy is a consultant for Pharmavite. The other authors declare no conflicts of interest.

546 **References**

 Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecol Oncol. 2017;147(3):705–13.

- Lyra PCM, Rangel LB, Monteiro ANA. Functional Landscape of Common Variants
 Associated with Susceptibility to Epithelial Ovarian Cancer. Curr Epidemiol Rep. 2020
 Mar 1;7(1):49–57.
- Kar SP, Berchuck A, Gayther SA, Goode EL, Moysich KB, Pearce CL, et al. Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2018;27(4):395–404.
- 4. Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, et al.
 Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in
 BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 01;109(7).
- 5. Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, et al. Polygenic
 risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and
 BRCA2 pathogenic variants. Genet Med Off J Am Coll Med Genet. 2020 Jul 15;
- 563 6. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease
 564 from genome-wide association studies. Genome Res. 2007 Oct;17(10):1520–8.
- International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM,
 O'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009 Aug 6;460(7256):748–52.
- Abraham G, Kowalczyk A, Zobel J, Inouye M. Performance and robustness of penalized and unpenalized methods for genetic prediction of complex human disease.
 Genet Epidemiol. 2013 Feb;37(2):184–95.
- 571 9. Habier D, Fernando RL, Kizilkaya K, Garrick DJ. Extension of the bayesian alphabet
 572 for genomic selection. BMC Bioinformatics. 2011 May 23;12:186.
- 573 10. Szymczak S, Biernacka JM, Cordell HJ, González-Recio O, König IR, Zhang H, et al.
 574 Machine learning in genome-wide association studies. Genet Epidemiol. 2009;33 Suppl 1:S51-57.
- 576 11. Privé F, Aschard H, Blum MGB. Efficient Implementation of Penalized Regression for
 577 Genetic Risk Prediction. Genetics. 2019;212(1):65–74.
- Mak TSH, Porsch RM, Choi SW, Zhou X, Sham PC. Polygenic scores via penalized
 regression on summary statistics. Genet Epidemiol. 2017;41(6):469–80.
- 13. Perren TJ. Mucinous epithelial ovarian carcinoma. Ann Oncol. 2016 Apr 1;27:i53–7.
- 14. Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, et al. The
 molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019
 02;10(1):3935.

- Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, et al.
 A combination of the immunohistochemical markers CK7 and SATB2 is highly
 sensitive and specific for distinguishing primary ovarian mucinous tumors from
 colorectal and appendiceal metastases. Mod Pathol Off J U S Can Acad Pathol Inc.
 2019;32(12):1834–46.
- 16. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al.
 Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian
 cancer. Nat Genet. 2017 May;49(5):680–91.
- 592 17. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
 593 resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9.
- Lawrenson K, Song F, Hazelett DJ, Kar SP, Tyrer J, Phelan CM, et al. Genome-wide
 association studies identify susceptibility loci for epithelial ovarian cancer in east Asian
 women. Gynecol Oncol. 2019;153(2):343–55.
- 19. Manichaikul A, Peres LC, Wang X-Q, Barnard ME, Chyn D, Sheng X, et al.
 Identification of novel epithelial ovarian cancer loci in women of African ancestry. Int J
 Cancer. 2020 Jun 1;146(11):2987–98.
- Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric
 Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis
 (DIAGRAM) Consortium, et al. Conditional and joint multiple-SNP analysis of GWAS
 summary statistics identifies additional variants influencing complex traits. Nat Genet.
 2012 Mar 18;44(4):369–75, S1-3.
- Vilhjálmsson BJ, Yang J, Finucane HK, Gusev A, Lindström S, Ripke S, et al.
 Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. Am J
 Hum Genet. 2015 Oct 1;97(4):576–92.
- Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian
 regression and continuous shrinkage priors. Nat Commun. 2019 16;10(1):1776.
- Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J,
 et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2
 Mutation Carriers. JAMA. 2017 20;317(23):2402–16.
- 613 24. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic Risk
 614 Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet.
 615 2019 03;104(1):21–34.
- Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al.
 Association analyses of more than 140,000 men identify 63 new prostate cancer
 susceptibility loci. Nat Genet. 2018;50(7):928–36.
- 619 26. Jia G, Lu Y, Wen W, Long J, Liu Y, Tao R, et al. Evaluating the Utility of Polygenic
 620 Risk Scores in Identifying High-Risk Individuals for Eight Common Cancers. JNCI
 621 Cancer Spectr. 2020 Jun;4(3):pkaa021.
- 622 27. Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, et al.
 623 Population distribution of lifetime risk of ovarian cancer in the United States. Cancer

- Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol.
 2015 Apr;24(4):671–6.
- Yang X, Leslie G, Gentry-Maharaj A, Ryan A, Intermaggio M, Lee A, et al. Evaluation
 of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study.
 J Med Genet. 2018;55(8):546–54.
- Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer Risks
 Associated With Germline PALB2 Pathogenic Variants: An International Study of 524
 Families. J Clin Oncol Off J Am Soc Clin Oncol. 2020 Mar 1;38(7):674–85.
- Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, et al.
 Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a
 susceptibility gene for high-grade serous ovarian cancer. J Med Genet. 2020 Jun 16;
- 635 31. Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, et al.
 636 BOADICEA: a comprehensive breast cancer risk prediction model incorporating
 637 genetic and nongenetic risk factors. Genet Med. 2019 Aug;21(8):1708–18.
- 638 32. Welcome to CanRisk [Internet]. [cited 2020 Aug 31]. Available from:
 639 https://www.canrisk.org/
- 640 33. Chen K, Ma H, Li L, Zang R, Wang C, Song F, et al. Genome-wide association study
 641 identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women.
 642 Nat Commun. 2014 Aug 19;5:4682.
- 34. Watkins WS, Rogers AR, Ostler CT, Wooding S, Bamshad MJ, Brassington A-ME, et
 al. Genetic variation among world populations: inferences from 100 Alu insertion
 polymorphisms. Genome Res. 2003 Jul;13(7):1607–18.
- Hu Y, Lu Q, Powles R, Yao X, Yang C, Fang F, et al. Leveraging functional annotations
 in genetic risk prediction for human complex diseases. PLoS Comput Biol. 2017
 Jun;13(6):e1005589.

649

Figure captions

Figure 1: PRS model development using penalized regression and LDPred Bayesian approach

Figure 2: Cumulative risk of ovarian cancer between birth and age 80 by PRS percentiles and PRS models. Shown are the cumulative risk of ovarian cancer risk in UK women by polygenic risk score percentiles. The lasso (A) and elastic net (B) penalized regression models were applied to individual level genotype data, while the stepwise (C) and S4 (D) models were applied to summary level statistics.

Figure 3: Association between the PLR PRS models and non-mucinous ovarian cancer by PRS percentiles. Shown are estimated odds ratios (OR) and confidence intervals for women of European ancestry by percentiles of polygenic risk scores derived from lasso (A), elastic net (B), stepwise (C) and S4 (D) models relative to the middle quintile.

Figure 1: PRS model development using penalized regression and LDPred Bayesian approach.



Figure 2: Cumulative risk of ovarian cancer between birth and age 80 by PRS percentiles and PRS models





Figure 3: Association between the PLR PRS models and non-mucinous ovarian cancer by PRS percentiles